The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study

The A2(A) receptor agonist, regadenoson, is increasingly used as a vasodilator during nuclear myocardial perfusion imaging. Regadenoson is administered as a single, fixed dose. Given the frequency of obesity in patients with symptoms of heart disease, it is important to know whether the fixed dose o...

Descripción completa

Detalles Bibliográficos
Autores principales: DiBella, Edward V. R., Fluckiger, Jacob U., Chen, Liyong, Kim, Tae Ho, Pack, Nathan A., Matthews, Brian, Adluru, Ganesh, Priester, Tiffany, Kuppahally, Suman, Jiji, Ronny, McGann, Chris, Litwin, Sheldon E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463785/
https://www.ncbi.nlm.nih.gov/pubmed/21968545
http://dx.doi.org/10.1007/s10554-011-9949-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463785/
https://www.ncbi.nlm.nih.gov/pubmed/21968545
http://dx.doi.org/10.1007/s10554-011-9949-4

Ejemplares similares